Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
SMMT
SUMMIT THERAPEUTICS INC.
NASDAQ
$17.40
▼ DOWN 5.54% (-1.02)

KEY STATISTICS

Market Cap$13.92 B
52w High$29.23
52w Low$12.07
Dividend Yield—
Frequency—
P/E-15.54
Volume5.79M
Shares Out.797.75M

COMPANY

LEADERSHIP

Robert W. Duggan
CHIEF EXECUTIVE
Robert W. Duggan

COMPENSATION 2026

Salary$0
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$172,376
Total$172,376

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 5, 2015
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
265

PRICE TARGET

Target High$38.00
Target Low$15.00
Target Median$25.00
Target Consensus$26.86

UPCOMING EARNINGS

DateOct 19, 2026
DayMonday
Rev. Est.$71.43K
OCT
19
MON

PRICE

$17.40 ▼ DOWN 5.54% (−$1.02)
$17.20$17.60$18.00$18.409:31 AM10:36 AM11:40 AM12:45 PM1:50 PM2:54 PM3:59 PM17.40

About Summit Therapeutics Inc.

https://www.smmttx.com ↗

Summit Therapeutics Inc. is a biopharma firm developing antibiotics like ridinilazole for infectious diseases, mainly CDI, in the U.S. and Latin America.

INDUSTRY

Biotechnology

A PRODUCT SUMMIT THERAPEUTICS INC. IS KNOWN FOR

Ivonescimab (SMT112)
Ivonescimab (SMT112)

Ivonescimab, a potential first-in-class bispecific antibody targeting PD-1 and VEGF, is in Phase III trials for cancer, including NSCLC, with a BLA submission to the FDA.

COMPETITORS

COMPETITOR
BMY COMPARE
BNTX COMPARE
MRK COMPARE
PFE COMPARE
REGN COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
133
LISTED HERE
26
RANKED BY POSITION SIZE
XBI
1.28% · 7.8M
VTS.AX
0.00% · 3.7M
IBB
0.17% · 1.0M
PINK
2.66% · 525.6K
SCHM
0.05% · 427.5K
LABU
0.97% · 284.3K
SBIO.MI
0.92% · 242.7K
ONEQ
0.03% · 192.1K
CANC
1.35% · 153.1K
ZUH.TO
1.29% · 96.4K
BBMC
0.05% · 59.5K
203780.KS
0.92% · 38.7K
PTL
0.07% · 37.5K
JHMM
0.01% · 27.0K
BIB
0.51% · 26.0K
CURE.AX
1.28% · 24.9K
BBC
0.85% · 22.7K
BKMC
0.06% · 20.6K
IQSM
0.08% · 16.4K
RECS
0.00% · 12.0K
TILT
0.00% · 5.3K
MSSM
0.01% · 4.5K
GUSA
0.00% · 4.4K
VETS
0.23% · 4.0K
TNXT
0.29% · 3.0K
STXV
0.02% · 760

INSTITUTIONAL OWNERSHIP

SHARES OWNED
14.98%
HOLDERS
361
TOP 12 OF 361 · RANKED BY POSITION SIZE
Baker Bros. Advisors LP
36.4M sh · $636.48M
Fmr LLC
13.4M sh · $233.68M
Vanguard Group Inc
11.4M sh · $235.11M
Blackrock, Inc.
9.7M sh · $183.04M
State Street Corp
9.5M sh · $138.95M
Price T Rowe Associates Inc /Md/
9.4M sh · $163.91M
Blackrock Inc.
7.9M sh · $61.61M
Ubs Group AG
5.2M sh · $76.26M
Polar Capital Llp
5.0M sh · $17.2M
Goldman Sachs Group Inc
4.5M sh · $65.76M
Point72 Asset Management, L.P.
3.7M sh · $53.88M
Geode Capital Management, LLC
3.4M sh · $49.95M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR, 10 PERCENT OWNER, OFFICER: CO-CHIEF EXECUTIVE OFFICER
DUGGAN ROBERT W
Purchase · 3.8M shares
2026-06-12
★
DIRECTOR, 10 PERCENT OWNER, OFFICER: CO-CHIEF EXECUTIVE OFFICER
Zanganeh Mahkam
Purchase · 3.8M shares
2026-06-12
★
DIRECTOR, 10 PERCENT OWNER, OFFICER: CO-CHIEF EXECUTIVE OFFICER
Zanganeh Mahkam
Purchase · 100.0K shares
2026-06-04
★
DIRECTOR, OFFICER: COO AND CFO
Soni Manmeet Singh
Purchase · 25.0K shares
2026-06-04

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
NEUTRAL 2
MARKET PERFORM 2
MARKET OUTPERFORM 2
EQUAL WEIGHT 1
11 GRADES IN THE LAST 12 MONTHS
Jefferies BUY HC Wainwright & Co. NEUTRAL Bernstein MARKET PERFORM Leerink Partners MARKET PERFORM Guggenheim BUY Stifel BUY Piper Sandler NEUTRAL Citizens MARKET OUTPERFORM

SECTORS PEERS

PEERPRICE
MRNA$144.39COMPARE
RVMD$203.46COMPARE
ROIV$39.61COMPARE
RPRX$58.37COMPARE
ASND$233.91COMPARE
BBIO$68.27COMPARE
UHS$176.77COMPARE
IONS$47.58COMPARE